Skip to main content
. 2024 Sep 16;14(1):160. doi: 10.1038/s41408-024-01140-5

Fig. 4. Baseline characteristics of t-AML patients with significant impact on OS (logrank-test).

Fig. 4

A Type of AML therapy, B ELN adverse risk, C sex differences, D age-related survival difference, E ECOG performance score, F comorbidity, G cardiovascular disease, H chronic renal insufficiency, I diabetes mellitus, J body weight, K active cancer disease, L preceeding therapies, M previous radio-iodine therapy, N Latency period to t-AML. n Number of patients, OS overall survival, t-AML therapy-related AML, ELN European LeukemiaNet, ECOG Eastern Cooperative Oncology Group, CCI Charlson comorbidity index, BMI body mass index.